STATEMENT -----------License and Collaborative Research Agreement • March 31st, 2003 • Hemoxymed Inc • Biological products, (no disgnostic substances)
ContractLicense and Collaborative Research Agreement • May 5th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Amendment #3 to License and Collaborative Research AgreementLicense and Collaborative Research Agreement • June 17th, 2021 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Amendment #3 to the License and Collaborative Research Agreement (“Amendment #3”), dated June 14, 2021 (“Amendment Effective Date”), amends the License and Collaborative Research Agreement, dated December 18, 2014 (the “Original Agreement”), by and between Novartis Institutes for BioMedical Research, Inc. (“Novartis”) and Intellia Therapeutics, Inc. (“Intellia”), as amended by the Extension Agreement, effective January 30, 2015 (the “First Amendment”), and the Agreement and Amendment, dated December 3, 2018 (the “Second Amendment”). The Original Agreement, as amended by the First Agreement and the Second Amendment, are hereby referred to as the “Agreement”. Novartis and Intellia are collectively referred to as the “Parties” and individually as a “Party”. Terms not otherwise defined in this Amendment #3 have the meaning set forth in the Agreement.
Agreement and Amendment to License and Collaborative Research AgreementLicense and Collaborative Research Agreement • February 27th, 2019 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Agreement and Amendment (the “Amendment”) dated December 3, 2018 (the “Amendment Effective Date”), is made by and between Novartis Institutes for BioMedical Research, Inc. (“Novartis”) and Intellia Therapeutics, Inc. (“Intellia”) and it amends the License and Collaborative Research Agreement (“Agreement”), effective December 18, 2014, by and between Novartis and Intellia, as amended by the Extension Agreement effective January 30, 2015 (the “Extension Agreement”). Novartis and Intellia are each separately referred to as a “Party” and are collectively referred to as the “Parties”. Capitalized terms not otherwise defined in this Amendment have the meanings set forth in the Agreement.
ContractLicense and Collaborative Research Agreement • May 6th, 2021 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
THIRD AMENDMENT AGREEMENTLicense and Collaborative Research Agreement • April 2nd, 2007 • Applied Neurosolutions Inc • Biological products, (no disgnostic substances)
This Third Amendment Agreement is made effective October 30, 2006 by and between Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 ("AECOM") and Applied NeuroSolutions, Inc. (formerly known as Molecular Geriatrics Corp.), a corporation organized and existing under the laws of the State of Delaware, having an office and place of business at 50 Lakeview Parkway, Suite 111, Vernon Hills, Illinois 60061 ("Licensee").
